Welcome to LookChem.com Sign In|Join Free

CAS

  • or

144656-11-1

Glycine, N-(4-cyanophenyl)-, 1,1-dimethylethyl ester, also known as tert-butyl N-(4-cyanophenyl)glycinate, is a chemical compound with the molecular formula C12H15NO2. It is a derivative of glycine, an essential amino acid, and is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals. As a tert-butyl ester, it has a bulky and stable structure, making it a valuable building block in organic synthesis and drug discovery.

144656-11-1 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 144656-11-1 Structure

  • Basic information

    1. Product Name: Glycine, N-(4-cyanophenyl)-, 1,1-dimethylethyl ester
    2. Synonyms:
    3. CAS NO:144656-11-1
    4. Molecular Formula: C13H16N2O2
    5. Molecular Weight: 232.282
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 144656-11-1.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: Glycine, N-(4-cyanophenyl)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
    10. NIST Chemistry Reference: Glycine, N-(4-cyanophenyl)-, 1,1-dimethylethyl ester(144656-11-1)
    11. EPA Substance Registry System: Glycine, N-(4-cyanophenyl)-, 1,1-dimethylethyl ester(144656-11-1)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 144656-11-1(Hazardous Substances Data)

144656-11-1 Usage

Uses

Used in Pharmaceutical Industry:
Glycine, N-(4-cyanophenyl)-, 1,1-dimethylethyl ester is used as an intermediate in the synthesis of various pharmaceuticals for its stable and bulky structure, which aids in the development of new drugs and medications.
Used in Agrochemical Industry:
Glycine, N-(4-cyanophenyl)-, 1,1-dimethylethyl ester is used as an intermediate in the synthesis of agrochemicals, contributing to the development of effective pesticides and other agricultural products.
Used in Fine Chemicals Industry:
Glycine, N-(4-cyanophenyl)-, 1,1-dimethylethyl ester is used as a building block in the synthesis of fine chemicals, enabling the creation of high-quality specialty chemicals for various applications.

Check Digit Verification of cas no

The CAS Registry Mumber 144656-11-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,4,6,5 and 6 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 144656-11:
(8*1)+(7*4)+(6*4)+(5*6)+(4*5)+(3*6)+(2*1)+(1*1)=131
131 % 10 = 1
So 144656-11-1 is a valid CAS Registry Number.

144656-11-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name (4-cyanophenylamino)-acetic acid tert-butyl ester

1.2 Other means of identification

Product number -
Other names N-(4-cyano-phenyl)-glycine-tert.-butylester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:144656-11-1 SDS

144656-11-1Relevant articles and documents

SUBSTITUTED PYRROLES AND METHODS OF USE

-

Page/Page column 36, (2010/01/07)

The invention relates to substituted pyrrole compounds of Formula (I) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chkl) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

Cyclic urea derivatives, pharmaceutical compositions containing these compounds and processes for preparing them

-

, (2008/06/13)

The invention relates to cyclic urea derivatives of general formula STR1 wherein Ra, Rb, X and Y are as defined herein, pharmaceutical compositions containing the derivatives and processes for preparing them.

Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists

Sall, Daniel J.,Arfsten, Ann E.,Bastian, Jolie A.,Denney, Michael L.,Harms, Cathy S.,McCowan, Jefferson R.,Morin Jr., John M.,Rose, Jack W.,Scarborough, Robert M.,Smyth, Mark S.,Um, Suzane L.,Utterback, Barbara G.,Vasileff, Robert T.,Wikel, James H.,Wyss, Virginia L.,Jakubowski, Joseph A.

, p. 2843 - 2857 (2007/10/03)

The use of 5,6-bicyclic amidines as arginine surrogates in the design of a novel class of potent platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa) antagonists is described. The additional conformational restriction offered by the bicyclic nucleus results in 20-400-fold increases in potency compared to the freely flexible, acyclic benzamidine counterpart. The design, synthesis, structure-activity relationships (SAR), and in vitro activity of this novel class of GPIIb-IIIa antagonists are presented.

Platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa) antagonists derived from amidinoindoles

Sall, Daniel J.,Arfsten, Ann E.,Berry, Dennis R.,Denney, Michael L.,Harms, Cathy S.,McCowan, Jefferson R.,Ray, Judith K.,Scarborough, Robert M.,Um, Suzane L.,Utterback, Barbara G.,Jakubowski, Joseph A.

, p. 81 - 86 (2007/10/03)

A series of substituted amidinoindoles have been prepared as mimics of the RGD sequence and were studied as antagonists of the platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa). The agents were potent and selective antagonists of GPIIb-IIIa. Compared to their acyclic counterparts, the amidinoindole series bound with 10- to 20-fold greater affinity, indicating the advantages of added conformational restriction and/or hydrophobicity in the basic region of RGD mimics.

Cyclic urea derivatives, pharmaceutical compositions containing these compounds and methods of using the same

-

, (2008/06/13)

The invention relates to cyclic urea derivatives of general formula STR1 wherein Ra, Rb, X and Y are as defined herein, pharmaceutical compositions containing the derivatives and processes for preparing them.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 144656-11-1